Trials / Unknown
UnknownNCT04805060
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2858 Injection in Subjects With Terminal Malignant Tumors
A Phase I, Open-label, Dose Escalation Study to Evaluate the Tolerance and Pharmacokinetics of TQB2858 Injection in Subjects With Terminal Malignant Tumor
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a phase I study to evaluate the safety and tolerability of TQB2858 injection in patients with advanced malignancy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2858 injection | TQB2858 administered intravenously (IV) on Day 1 of each 21-day. The established dose of TQB2858 is diluted with normal saline \[0.9% (w/v) sodium chloride solution\], and the infusion time is 60 ± 10 min. |
Timeline
- Start date
- 2021-04-23
- Primary completion
- 2021-12-12
- Completion
- 2025-12-12
- First posted
- 2021-03-18
- Last updated
- 2021-06-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04805060. Inclusion in this directory is not an endorsement.